Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
NCT03535506 · Georgetown University · PHASE2 · terminated · last registry update 2025-09-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of accrual” | – | Registry record, Georgetown University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CCND1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-24Results posted on the registry: Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-24Also stopped (terminated): Tvardi Therapeutics, Incorporated, TTI-101 + Palbociclib (NCT05384119)
- 2026-09-03Phase 3 first posted: SWOG Cancer Research Network, NSAI + CDK4/6i + NSAI + CDK4/6i + Capivasertib (NCT07802626)
- 2026-07-22Also stopped (terminated): M.D. Anderson Cancer Center, Everolimus + Neratinib (NCT03065387)
- 2026-07-21Phase 3 first posted: UNICANCER, a drug against CCND1 (NCT07717450)
- 2026-07-06Phase 3 first posted: Daiichi Sankyo, Trastuzumab deruxtecan + Trastuzumab (NCT07683754)
- 2026-06-25Also stopped (terminated): SOLTI Breast Cancer Research Group, Ribociclib + Letrozole OR Fulvestrant + Palbociclib + Letrozole OR Fulvestrant (NCT05207709)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-25Phase 3 first posted: BeOne Medicines, BGB-43395 + Letrozole (NCT07492641)
- 2026-02-24Results posted on the registry: City of Hope Medical Center, Fulvestrant + Letrozole (NCT02778685)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2026-02-12Results posted on the registry: Alliance Foundation Trials, LLC., palbociclib + trastuzumab (NCT02947685)
- 2026-01-13Results posted on the registry: Aileron Therapeutics, Inc., ALRN-6924 (NCT02264613)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-12Also stopped (terminated): NiKang Therapeutics, Inc., NKT2152 + palbociclib (NCT05935748)
- 2025-09-15Phase 3 first posted: Eli Lilly and Company, LY4064809 + Placebo (NCT07174336)
- 2025-09-11Also stopped (terminated): Sanofi, Amcenestrant-matching placebo + SAR439859 (NCT04478266)
- 2025-07-11Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid (NCT07061717)
- 2025-06-05Phase 3 first posted: Fudan University, Chemotherapy + CDK4/6 Inhibitor (NCT07005557)
- 2025-05-31Results posted on the registry: Sudipto Mukherjee, MD, PhD, MPH, Palcociclib + CPX-351 (NCT03844997)
- 2025-03-24Results posted on the registry: Fundacion Oncosur, Combination, Palbociclib + Binimetinib (NCT04494958)
- 2025-02-17Results posted on the registry: M.D. Anderson Cancer Center, Hydroxychloroquine + Letrozole (NCT03774472)
- 2025-02-17Results posted on the registry: Emory University, Anastrozole + Exemestane (NCT03691493)
- 2025-01-07Phase 3 first posted: Pfizer, PF-07220060 + letrozole (NCT06760637)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision